Your browser doesn't support javascript.
loading
Effectiveness of Maternal Influenza Vaccination in Peru PRIME Cohort.
Owusu, Daniel; Dawood, Fatimah S; Azziz-Baumgartner, Eduardo; Tinoco, Yeny; Soto, Giselle; Gonzalez, Oswaldo; Cabrera, Santiago; Florian, Richard; Llajaruna, Edwin; Hunt, Danielle Rentz; Wesley, Meredith G; Yau, Tat; Arriola, Carmen S.
Afiliación
  • Owusu D; Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Dawood FS; Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Azziz-Baumgartner E; Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Tinoco Y; U.S. Naval Medical Research Unit No. 6, Bellavista, Peru.
  • Soto G; U.S. Naval Medical Research Unit No. 6, Bellavista, Peru.
  • Gonzalez O; Instituto Nacional Materno Perinatal, Lima, Peru.
  • Cabrera S; Hospital Nacional Docente Madre Niño San Bartolomé, Lima, Peru.
  • Florian R; Hospital Nacional Arzobispo Loayza, Lima, Peru.
  • Llajaruna E; Hospital Nacional Dos de Mayo, Lima, Peru.
  • Hunt DR; Abt Associates, Inc., Atlanta, Georgia, USA.
  • Wesley MG; Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Yau T; Abt Associates, Inc., Atlanta, Georgia, USA.
  • Arriola CS; Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Open Forum Infect Dis ; 10(2): ofad033, 2023 Feb.
Article en En | MEDLINE | ID: mdl-36817741
Background: Few studies have examined influenza vaccine effectiveness (VE) among women during pregnancy in middle-income countries. We used data from a prospective cohort of women who were pregnant in Peru to estimate effectiveness of the 2018 Southern Hemisphere influenza vaccine. Methods: Women at <28 weeks gestation were enrolled from 4 tertiary level hospitals in Lima, Peru at the start of the 2018 influenza season and followed until the end of their pregnancies. Participants had mid-turbinate nasal swabs collected and tested for influenza by reverse-transcription polymerase chain reaction (RT-PCR) with onset of ≥1 of myalgia, cough, runny nose or nasal congestion, sore throat, or difficulty breathing. Time-varying Cox proportional hazard regression models were used to estimate the risk of RT-PCR-confirmed influenza infection after adjusting for inverse probability treatment weight. Results: We followed 1896 women for a median of 127 days (interquartile range [IQR], 86-174). Participants had a median age of 29 years (IQR, 24-34). Among the 1896 women, 49% were vaccinated with the 2018 influenza vaccine and 1039 (55%) developed influenza-like illness, 76 (7%) of whom had RT-PCR-confirmed influenza. Incidence rates of RT-PCR-confirmed influenza were 36.6 and 15.3 per 100 000 person-days among women who were unvaccinated and vaccinated, respectively. Adjusted influenza VE was 22% (95% confidence interval, -64.1% to 62.9%). Conclusions: Participants vaccinated against influenza had more than 50% lower incidence of RT-PCR-confirmed influenza illness. Although the VE estimated through propensity weight-adjusted time-varying Cox regression did not reach statistical significance, our findings provide additional evidence about the value of maternal influenza vaccination in middle-income countries.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies País/Región como asunto: America do sul / Peru Idioma: En Revista: Open Forum Infect Dis Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies País/Región como asunto: America do sul / Peru Idioma: En Revista: Open Forum Infect Dis Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos